key regulatory role. 5 Members of the panoply of PDEs can be targeted to specific subcellular sites 11 and interact with anchor/scaffold proteins, including A kinase anchoring proteins. 12, 13 PDEs are grouped in a superfamily, of which 8 families hydrolyze cAMP. 5, 11 Their species-conserved diversity suggests that different isoforms play specific roles and, indeed, lack of redundancy in the PDE4 subfamily has been inferred from gene knockout studies. 14 PDEs differ not only in terms of intracellular targeting but also in activity, K m , modulation, and expression. 5 PDEs are ideally suited to fix the boundaries for cAMP diffusion and thereby modulate defined sets of PKA-mediated events. 1, 7, 8, 15 Although PDE activity in cardiac myocytes has been studied in some detail, 16 -18 the contribution of individual PDE families in shaping the cAMP response to specific stimuli remains largely to be determined.
By directly measuring cAMP, we dissect the role of particular PDE families in the control of cAMP concentration in basal conditions and on ␤-AR stimulation, and provide direct evidence for distinct roles of PDE3 and PDE4 in forming and shaping cAMP transients in cardiomyocytes.
Materials and Methods

Chemicals and Reagents
Norepinephrine, rolipram, isobutyl-methyl-xanthine (IBMX), and cilostamide were from Sigma-Aldrich. Anti PDE3A antibody was from FabGennix Inc (Shreveport, La).
Immunopurification of PDE4 Subfamilies for PDE Assay and Western Blots
This was performed as described before. 19, 20 Briefly, insoluble proteins were removed from the lysate by centrifugation at 10 000g av for 20 minutes and the soluble fraction retained. The activity of individual PDE4 subfamilies was determined as before by quantitative immunopurification using specific antisera, 19, 20 except here a rodent PDE4A-specific antisera 20, 21 was used to immunopurify PDE4A. Western blotting of PDE4 isoforms was performed as before using C-terminal directed antisera. 22, 23 Phosphodiesterase Assay PDE activity was assayed using a modification of the Thompson and Appleman 2-step procedure 24 as described. 25 Protein concentration was determined using the Bradford method. 26 
Dominant-Negative PDE4
As described before, 11 mutation of aspartate to alanine in the catalytic site renders PDE4 catalytically inactive with a dominantnegative function. Here we used the catalytically inactive D556A-PDE4D5 and D392A-PDE4B2 constructs.
Immunostaining and Confocal Imaging
Cells were costained with anti-PDE and anti-alpha actinin antibodies (Sigma). Alexa fluor 488-conjugated antimouse antibody and Alexa fluor 543-conjugated antigoat antibody (Molecular Probes, Eugene, Ore) were used as secondary antibodies. Confocal images were acquired with a Bio-Rad 2100MP confocal system.
Fluorescence Resonance Energy Transfer Imaging
Primary cultures of cardiac ventricular myocytes from 1-to 2-dayold Sprague Dawley rats were prepared as described. 27 After transfection with C-YFP and RII-CFP, 28 cells were imaged on an inverted Olympus IX50 microscope, equipped with a cooled chargecoupled device camera (Sensicam QE), a software-controlled monochromator (TILL Photonics), and a beam-splitter optical device (Microimager). Images were acquired using a custom-made software and processed using ImageJ (Rasband). Fluorescence resonance energy transfer (FRET) changes were measured as changes in the 480 nm/535 nm fluorescence emission intensities on excitation at 430 nm. Cells were perfused with HEPES-buffered Ringer modified saline (1 mmol/L CaCl 2 ) at room temperature (20°C to 22°C). Norepinephrine pulses were delivered by means of a softwarecontrolled pressurized micropipette in proximity of the analyzed cell and loaded with a 1 mol/L norepinephrine.
Results
PDE Activity in Homogenates of Rat Neonatal Cardiac Myocytes
Lysates of neonatal rat cardiac myocytes expressed cAMP PDE activity at a level of 102Ϯ8 pmol min Ϫ1 mg protein
Ϫ1
with 1 mol/L cAMP as substrate (meanϮSD; nϭ8). PDE3 and 4 are believed to provide the major cAMP PDE activity in rat myocytes. 29 We determined lysate PDE3 and PDE4 activities using the highly selective inhibitors, cilostamide (10 mol/L) and rolipram (10 mol/L), 11, 30, 31 respectively. Figure 1A shows that Ϸ90% of the activity is provided by these 2 families, with the activity of PDE4 being double that of PDE3. PDE4 comprises 4 subfamilies with various isoforms. 11 Using antisera that identify all isoforms within a particular subfamily, 19, 20 we immunopurified each PDE4 subfamily for PDE assay. PDE4D and PDE4B together provide Ϸ90% of the total PDE4 activity, with PDE4D activity being double that of PDE4B, whereas PDE4A and PDE4C contribute Ͻ10% of total PDE4 activity ( Figure 1B ). Western blotting of lysates with specific antisera identified a single band comigrating with the short-form PDE4B2 recombinant standard ( Figure 1C ) and 2 bands comigrating with the long-form PDE4D3 and PDE4D5 recombinant standards ( Figure 1D ). The expression level of PDE4D3 was considerably greater than that of PDE4D5. 12, 32 
Individual PDE Families Play a Different Role in the Control of [cAMP] i in Resting Cardiomyocytes
The genetically encoded sensor for cAMP levels we developed 8, 28 is based on FRET between a donor (CFP) and an acceptor fluorophore (YFP) fused to the regulatory (R) and catalytic (C) subunits of PKA, respectively. With this sensor, changes in cAMP concentration ([cAMP] i ) can be estimated The activity of each subfamily is expressed as a percentage of the total PDE4 activity. Data are meansϮSD for 3 experiments. Immunopurification was performed using PDE4 subfamily-specific antisera (see Methods). C and D, Western blots using PDE4B-and PDE4D-specific antisera, respectively. Lysate protein (100 g) was used against recombinant standards for (C) PDE4B2 and (D) PDE4D3 and PDE4D5. These blots are typical and were performed at least 3 times.
by changes in FRET measured as changes in the CFP-to-YFP emissions ratio (480 nm/545 nm), a value that is proportional to ([cAMP] i ). Figure 2A shows the cAMP-dependence of the probe in vitro as compared with its ability to phosphorylate the PKA peptide substrate Kemptide. The 2 assays gave identical EC 50 values (Ϸ0.3 mol/L). Changes in FRET were expressed as the percent 480 nm/545 nm emission increase over the 480 nm/545 nm value at time 0 seconds (⌬R/R 0 ).
As mentioned previously, 8 treatment of the myocytes with a saturating (100 mol/L) dose of the nonselective PDE inhibitor, IBMX, induces a maximal response (⌬R/R 0 of 9Ϯ1.2%, meanϮSEM; nϭ10) ( Figure 2B and 2E) because no further increase was caused by subsequent addition of a saturating concentration (50 mol/L) of the nonselective AC activator forskolin 33 (not shown). The velocity of the [cAMP] i increase measured as (⌬R/R 0 )/second was 0.17Ϯ0.03%/second (nϭ10).
We focused on evaluating the effects of selectively inhibiting the major PDE activities, PDE3 and PDE4. As a control, IBMX (100 mol/L) was used to inhibit both PDEs. PDE3 inhibition with cilostamide (1 mol/L) increased [cAMP] i with a ⌬R/R 0 of 1.7Ϯ0.4% and a (⌬R/R 0 )/second of 0.06Ϯ0.01%/second (nϭ10) ( Figure 2C and 2E). Cilostamide action was transient, with the signal returning back to the baseline by 93Ϯ6 seconds. In contrast, PDE4 inhibition with rolipram (1 mol/L) generated a much larger (⌬R/ R 0 ϭ11.5Ϯ0.9%; nϭ12) and faster [(⌬R/R 0 )/⌬ secondsϭ0.25Ϯ0.03%/seconds] increase of the signal ( Figure  2D and 2E). In 40% of rolipram-treated cells, the increase in cAMP reached a sustained plateau, whereas in the remaining 60% the increase was partially reversible, reaching a plateau level at Ϸ70% of the peak 220Ϯ50 seconds after rolipram application ( Figure 2D ). These results indicate that PDE4 provides the major role in controlling [cAMP] i under resting conditions.
Action of PDE3 and PDE4 Inhibition on the ␤-Adrenergic Receptor-Stimulated cAMP Response
Myocytes challenged with a submaximal (5 nmol/L) dose of the ␤-agonist norepinephrine generated a transient ⌬R/R 0 Ϸ2% over basal, returning to near initial levels in 107Ϯ9.6 seconds ( Figure 3A and 3E). A subsequent addition of cilostamide caused a further increase in ⌬R/R 0 of 3.6Ϯ1.3% (nϭ5) ( Figure 4A and 4E), with (⌬R/R 0 )/secondϭ0.06Ϯ 0.01%/second. This increase was approximately twice that induced by cilostamide in unstimulated cells and was again transient (171Ϯ26.6 seconds).
Inhibition of PDE4 with 1 mol/L rolipram causes a maximal response of the probe ( Figure 2D and 2E). Thus, to assess the effect of PDE4 inhibition in norepinephrine-stimulated cells, we used a concentration (25 nmol/L) of rolipram that, in unstimulated conditions, exerts a minimal effect on [cAMP] i ( Figure 3B and 3E) and inhibits Ϸ10% of total PDE4 ( Figure 3C ). Under these conditions, 5 nmol/L norepinephrine causes ( Figure 3D ) a maximal and sustained response [⌬R/R 0 ϭ9Ϯ2%, and (⌬R/R 0 )/ secondϭ0.05Ϯ0.01%/second; nϭ5].
The probe shows that PDE4 inhibition is profoundly more effective than PDE3 inhibition in potentiating norepinephrineinduced cAMP accumulation. We also examined total cAMP accumulation in myocytes using a radioimmunoassay. Inhibition of PDE4 with rolipram (1 mol/L) was profoundly more effective than inhibition of PDE3 with cilostamide (1 mol/L) on the ability of norepinephrine to increase cAMP levels ( Figure 3F ).
Role of PDE3 and PDE4 Inhibition in Modulating the Duration of the cAMP Response to ␤-Adrenergic Receptor Stimulation
PDE3 and PDE4 not only contribute differently to determine the amplitude of the cAMP response but also have different effects on the kinetics of this response, being transient subsequent to PDE3 inhibition yet sustained on PDE4 blockade ( Figures 2C, 2D, 3A, and 3D ). These 
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distinct actions were confirmed in experiments in which myocytes were first treated with the indicated PDE inhibitor and subsequently challenged with a pulse (5 seconds) of a saturating concentration (1 mol/L) of norepinephrine. Figure 4A and 4B show that this norepinephrine pulse, administered in the presence of cilostamide, generated a response that was 1.5-fold higher than controls (norepinephrine alone), whereas the duration was indistinguishable (20Ϯ2.1 seconds, nϭ8; Figure 4A and 4C) from controls. In contrast, treatment of cells with low concentrations (25 nmol/L) of rolipram generated a response that was not only 2-fold higher than controls ( Figure 4A and 4B) but also considerably more sustained (time to half maximal decay 78Ϯ9 seconds, nϭ15) ( Figure 4A and 4C) . Thus, even in the presence of high concentrations of norepinephrine, PDE4 plays the key role in determining amplitude and duration of the cAMP response.
PDE4 Is Necessary and Sufficient for Terminating the cAMP Transient in Response to ␤-Adrenergic Receptor Stimulation
To investigate whether PDE4 is primarily responsible for terminating the increase of [cAMP] i in response to norepinephrine, myocytes were challenged with ␤-agonist while perfused with high concentrations of rolipram (1 mol/L). Because complete PDE4 inhibition generates an increase in [cAMP] i that is sufficient by itself, to saturate the probe ( Figure 2D and 2E) we generated a variant of the sensor (R230K) with reduced cAMP sensitivity (unpublished data 2004). 34 This new probe detects cAMP levels that would completely saturate the wild-type sensor (compare Figure 5A with Figure 3E ). For complete saturation of the R230K mutant probe, 100 mol/L IBMX plus 100 nmol/L norepinephrine are necessary ( Figure 5A ). The reduced sensitivity to cAMP of the R230K probe is confirmed by a higher (31.3Ϯ1.68mol/L) EC 50 value for dissociation as compared with the wild-type probe (Figure 2A ). Treatment of myocytes expressing the R230K probe with 100 nmol/L norepinephrine in the presence of rolipram (1 mol/L) not only causes a further increase in [cAMP] i (⌬R/R 0 ϭ5.2Ϯ0.8%, nϭ4) but also sustains it for at least 10 minutes ( Figure 5B ).
PDE3 and PDE4 Provide Distinct Functional Roles in Determining cAMP Levels
The different effects of PDE3 and PDE4 inhibitors on resting and ␤AR-induced increase of [cAMP] i suggest that these 2 enzyme families may reside in distinct compartments. Thus, we assessed the effect of selective PDE inhibitors on the cAMP response in cells in which the entire AC pool was activated by forskolin.
As shown in Figure 6 , treatment with low forskolin (100 nmol/L) alone generated a small response (⌬R/ R 0 ϭ1.05Ϯ0.39%; nϭ10). The subsequent addition of cilostamide (1 mol/L) generated a marked increase in cAMP levels with a ⌬R/R 0 of 5.9Ϯ1.1% (nϭ5) and a ⌬R/R 0 /second of 0.08Ϯ0.01%/second ( Figure 6A and 6C) . Again, these were transient, returning to baseline in 182Ϯ29 seconds, compatible with PKA-mediated activation of PDE4. 35 Addition of 25 nmol/L rolipram to cells pretreated with low forskolin generated a sustained increase in signal with a ⌬R/R 0 of 3.7Ϯ1.2% (nϭ5) and a ⌬R/R 0 /second of 0.04Ϯ0.01%/second ( Figure 6B and 6C) . Thus, selective PDE inhibition generates strikingly different effects on
[cAMP] i when AC is activated by forskolin or via ␤-AR. In the presence of forskolin, rolipram enhanced ⌬R/R 0 0.6 times compared with cilostamide, whereas with norepinephrine, rolipram amplified the response 2.2 times compared with cilostamide ( Figure 6D ). We attempted to estimate the size of the ␤-AR-sensitive pool of AC by transfecting myocytes with the R230K probe and comparing the cAMP response caused by saturating (10 mol/L) norepinephrine or with the maximal cAMP response obtained in the presence of total AC activation (10 mol/L norepinephrine plus 25 mol/L forskolin). The pool of AC activated by norepinephrine is, at most, 75Ϯ4% (nϭ5) of the total ACs.
Localization of PDE3 and PDE4 Families
Our results prompted us to investigate whether PDE3 and PDE4 may have distinct subcellular localizations using immunocytochemistry and confocal microscopy. PDE3A displayed nonhomogeneous trabecular staining ( Figure 7A through 7D) compatible with localization on internal membranes. In contrast, both PDE4B and 4D Abs identified a low-signal granular pattern in the cytosol and a much stronger signal in a striated pattern ( Figure 7E through 7I) . The PDE4B signal intercalated with the striated pattern of ␣-actinin, suggestive of localization to the sarcomeric M-line ( Figure 7E through 7H) , whereas PDE4D showed a striated pattern superimposable with that of ␣-actinin, suggestive of localization to the Z-line ( Figure 7I through 7L) . PKA shows a striated pattern in correspondence to the M and Z lines ( Figure 8M through 8P) .
Knowledge of the 3-dimensional structure of the PDE catalytic unit has allowed catalytically inactive PDE4 isoforms to be generated by single point mutation. 32 Expression of such inactive PDE4 has been shown 32 to exert a dominantnegative effect by displacing the cognate endogenous, active PDE4 isoform from its functionally relevant anchor site and thus, presumably, allowing localized cAMP levels around such anchor sites to be raised. As an initial attempt to 
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determine if the different location of PDE4B and PDE4D confers a specific function to these 2 subfamilies, we measured the kinetics of cAMP response on challenge with a pulse (5 seconds) of 1 mol/L norepinephrine in cells transfected with either dominant-negative PDE4B2 or dominant-negative PDE4D5, dominant-negative constructs. We detected a small but significant delay in the time required for the cAMP transient to return to baseline in cells expressing the dominant-negative PDE4B2 (time to half maximal decayϭ22.5Ϯ1.1) as compared with either the control (15.8Ϯ1.2) or the dominant-negative PDE4D5-expressing cells (19Ϯ2) (Figure 8 ). Such delay was amplified when total endogenous PDE4 activity was partially inhibited with of 25 nmol/L rolipram (time to half maximal decay 107Ϯ11 for PDE4B2 dominant-negative-expressing cells, 72Ϯ6 for control cells, and 73Ϯ7 for PDE4D5 dominant-negativeexpressing cells). These results suggest that PDE4B2 plays a major role in the control of the duration of the cAMP transient in response to norepinephrine and that this function is dependent on its location within the cell.
Discussion
Consistent with earlier studies, 29, 36 PDE3 and PDE4 provide the major cAMP PDE activity in cardiac myocytes. PDEs from multiple gene families are invariably coexpressed within the same cell; however, much remains to be understood as to how PDEs are engaged in the control of basal [cAMP] i and changes in response to ␤AR stimulation. We exploit the high sensitivity and temporal resolution of the FRET-based imaging approach to measure real-time kinetics of PKA activation in the presence of physiological concentration of agonist, a measure difficult to obtain by radioimmunoassay. 5 PDE3 affinity for cAMP is known to be higher than that of PDE4; 37 therefore, PDE3 is thought to control cAMP levels in basal conditions. 38 However, the increase in [cAMP] i was much smaller on inhibition of PDE3 than on inhibition of PDE4 ( Figure 2C and 2D 30 We observed a striking difference between PDE3 and PDE4 inhibition in the control of [cAMP] i on ␤AR stimulation. Thus, in the presence of norepinephrine, inhibition of Ϸ10% of total PDE4 (as obtained with 25 nM rolipram, Figure 3C ), resulted in a dramatic increase in cAMP, whereas total PDE3 inhibition had only a marginal effect ( Figure 3E ). A similar difference was seen for changes in "bulk" cAMP determined immunochemically in cell lysates ( Figure 3F ). These data indicate a functional coupling of PDE4, rather than PDE3, with a pool of AC that is activated in response to ␤AR stimulation. In contrast, when the entire cellular pool of AC was stimulated with forskolin, complete inhibition of PDE3 had an effect that was now clearly greater than that caused by a partial inhibition of PDE4 ( Figure 6 ). The fact that inhibition of only Ϸ10% of total PDE4 has such profound effect on the norepinephrine-generated cAMP transient suggests that compartmentation of PDEs may be equally important as their expression level.
We show that PDE4 has the potential to play a prominent role in regulating catecholamine-induced increases in [cAMP] i . It will be interesting to see if this occurs in those species, including humans, in which, unlike rats, PDE4 does not represent the major quota of total PDE activity in heart tissue. 40 Considerable attention has been focused on the regulation of PDE3 in the development of cardiomyopathy, particularly heart failure. 41 PDE3 inhibitors were originally developed as therapeutic agents to counteract the reduced synthesis of cAMP found in failing hearts. However, trials with milrinone were interrupted because chronic treatment resulted in increased mortality. 42 The reasons for such adverse effects are still to be elucidated, but it is conceivable that they may in part have resulted from a nonselective elevation of cAMP in multiple compartments and indiscriminate activation of PKA 43 (milrinone can affect both PDE4 and PDE3). 44 Little, however, is known about the role for PDE4 in human heart pathology. Our data suggest that alterations in PDE4 activity may influence ␤AR signaling in the heart. Recent evidence 45 shows that ␤AR agonist can cause PDE4D to be recruited to the ␤AR in complex with ␤-arrestin. Our data indicate that even a modest hyperactivity of PDE4 may result in an appreciable blunting of the cAMP response to catecholamines, whereas a reduced activity of PDE4 may lead to an exaggerated response in terms of amplitude and duration. Interestingly, an increase in PDE4 activity from 20% to 39% of the total PDE activity has been documented in failing hearts in dogs. 41 It is tempting to speculate that an increased activity and/or a mistargeting of PDE4 enzymes may contribute to reduce the inotropic response to milrinone observed in severe heart failure.
PDEs have been suggested to contribute to the compartmentation of cAMP signaling. 8, 46 In particular, a key role for PDE3 and PDE4 in limiting the diffusion of cAMP from the plasma membrane to the cytosol of frog ventriculocytes has been proposed. 15 Our data provide new insights to the concept of compartmentalized cAMP signaling and suggest a model whereby PDEs from distinct families independently and coordinately modulate [cAMP] i in selected functional compartments. We propose that PDE4 is primarily associated with regulating cAMP emanating from the ␤AR-activated AC domain. That ␤AR agonist challenge causes the ␤-arrestin-mediated recruitment of PDE4 to ␤ 2 AR in rat cardiac myocytes 45 demonstrates that PDE4 and ␤AR can be physically coupled in this cell type. We have shown that PDE3 and PDE4 have distinct localization, consistent with earlier biochemical studies in cardiac tissue. 47, 48 It is likely that such compartmentalization of cAMP signaling controlled by PDE3 and PDE4 will have functional consequences, and this is consistent with the different effects that selective inhibitors of these exert on various cell types. 30 Rolipram treatment of guinea pigs, despite increasing cAMP levels, is unable to alter the phosphorylation status of phospholamban and troponin I. 49 In conclusion, the spatial confinement of different PDEs to discrete compartments and their functional coupling to individual receptors may provide an efficient way to control local levels of cAMP in a stimulus-specific manner. This prompts the possibility of developing novel therapeutic approaches to correct cAMP imbalance in heart tissue.
